$EVOK
Evoke Pharma Inc

2022 Q1 Form 10-Q Financial Statement

#000156459022019277 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $418.4K $90.42K
YoY Change 362.7%
Cost Of Revenue $22.76K $60.00K
YoY Change -62.07%
Gross Profit $395.6K $30.00K
YoY Change 1218.73%
Gross Profit Margin 94.56% 33.18%
Selling, General & Admin $2.405M $2.338M
YoY Change 2.86% 75.83%
% of Gross Profit 607.93% 7794.32%
Research & Development $41.72K $277.8K
YoY Change -84.98% -40.1%
% of Gross Profit 10.54% 926.08%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.470M $2.681M
YoY Change -7.88% 49.46%
Operating Profit -$2.051M -$2.590M
YoY Change -20.82% 44.42%
Interest Expense -$122.5K $123.3K
YoY Change -199.31% 3551.24%
% of Operating Profit
Other Income/Expense, Net $0.00 -$15.05K
YoY Change -100.0% -545.38%
Pretax Income -$2.174M -$2.610M
YoY Change -16.72% 45.81%
Income Tax
% Of Pretax Income
Net Earnings -$2.174M -$2.605M
YoY Change -16.57% 45.53%
Net Earnings / Revenue -519.54% -2881.52%
Basic Earnings Per Share -$0.80
Diluted Earnings Per Share -$795.8K -$83.76K
COMMON SHARES
Basic Shares Outstanding 2.731M
Diluted Shares Outstanding 2.731M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.701M $18.19M
YoY Change -57.66% 340.44%
Cash & Equivalents $7.700M $18.19M
Short-Term Investments
Other Short-Term Assets $627.4K $620.0K
YoY Change 1.19% 55.0%
Inventory $278.8K $240.0K
Prepaid Expenses
Receivables $418.9K $130.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $9.026M $19.18M
YoY Change -52.94% 323.4%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $120.0K
YoY Change -100.0% 9.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $0.00 $116.0K
YoY Change -100.0% 5.41%
TOTAL ASSETS
Total Short-Term Assets $9.026M $19.18M
Total Long-Term Assets $0.00 $116.0K
Total Assets $9.026M $19.30M
YoY Change -53.22% 315.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $944.5K $690.0K
YoY Change 36.88% -25.81%
Accrued Expenses $412.2K $550.0K
YoY Change -25.05% -30.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.357M $6.249M
YoY Change -78.29% 264.11%
LONG-TERM LIABILITIES
Long-Term Debt $5.000M $5.000M
YoY Change 0.0%
Other Long-Term Liabilities $735.6K $240.0K
YoY Change 206.49%
Total Long-Term Liabilities $5.736M $5.236M
YoY Change 9.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.357M $6.249M
Total Long-Term Liabilities $5.736M $5.236M
Total Liabilities $7.092M $11.48M
YoY Change -38.25% 567.71%
SHAREHOLDERS EQUITY
Retained Earnings -$101.5M
YoY Change 15.96%
Common Stock $109.3M
YoY Change 20.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.934M $7.811M
YoY Change
Total Liabilities & Shareholders Equity $9.026M $19.30M
YoY Change -53.22% 316.05%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$2.174M -$2.605M
YoY Change -16.57% 45.53%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.615M -$2.953M
YoY Change -45.31% 90.29%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $13.07M
YoY Change 61406.61%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 171.5K 13.07M
YoY Change -98.69% 61406.61%
NET CHANGE
Cash From Operating Activities -1.615M -2.953M
Cash From Investing Activities
Cash From Financing Activities 171.5K 13.07M
Net Change In Cash -1.444M 10.12M
YoY Change -114.27% -760.97%
FREE CASH FLOW
Cash From Operating Activities -$1.615M -$2.953M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2022Q1 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
22760
CY2021Q1 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
64751
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
41717
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
277825
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2405075
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2338295
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
2469552
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13070154
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1443509
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
2680871
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2051172
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2590450
CY2021Q1 evok Forgiveness Of Paycheck Protection Loan And Accrued Interest
ForgivenessOfPaycheckProtectionLoanAndAccruedInterest
105130
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3164
CY2021Q1 us-gaap Interest Expense
InterestExpense
123339
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32777294
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31158065
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3555094
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
381061
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3548
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
171521
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1934011
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1304846
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2605495
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
7811384
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2173665
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2605495
CY2021Q1 evok Forgiveness Of Paycheck Protection Loan And Accrued Interest1
ForgivenessOfPaycheckProtectionLoanAndAccruedInterest1
-105130
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
381061
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
561348
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
123717
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
104484
CY2022Q1 evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-227100
CY2021Q1 evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-359617
CY2022Q1 evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
58022
CY2021Q1 evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-603164
CY2022Q1 evok Accrued Compensation
AccruedCompensation
107119
CY2021Q1 evok Accrued Compensation
AccruedCompensation
587438
CY2022Q1 evok Accrued Interest Expense
AccruedInterestExpense
123288
CY2021Q1 evok Accrued Interest Expense
AccruedInterestExpense
122589
CY2021Q1 evok Increase Decrease In Deferred Rent Expense
IncreaseDecreaseInDeferredRentExpense
-9038
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1615030
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2953119
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13070154
CY2022Q1 evok Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
171521
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
171521
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10117035
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
0
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
26000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
35000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9144710
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8068939
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7701201
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18185974
CY2021Q1 us-gaap Loans Assumed1
LoansAssumed1
105130
CY2022Q1 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7700000
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q1 evok Bad Debt Expense
BadDebtExpense
0
CY2021Q1 evok Bad Debt Expense
BadDebtExpense
0
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
150000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
150000
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
102000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7234138
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5425466
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2017Q4 evok Common Stock Shares To Be Issued Value
CommonStockSharesToBeIssuedValue
16000000.0
CY2021 evok Issuance Of Common Stock From Warrant Exercise Shares
IssuanceOfCommonStockFromWarrantExerciseShares
0
CY2021 evok Class Of Warrant Or Right Number Of Securities Expired
ClassOfWarrantOrRightNumberOfSecuritiesExpired
162206
CY2022Q1 evok Issuance Of Common Stock From Warrant Exercise Shares
IssuanceOfCommonStockFromWarrantExerciseShares
0
CY2022Q1 evok Class Of Warrant Or Right Number Of Securities Expired
ClassOfWarrantOrRightNumberOfSecuritiesExpired
1667673
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1679673
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.50
CY2022Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-10-31
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
87000
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.90
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
381061
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
561348
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2700000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D

Files In Submission

Name View Source Status
0001564590-22-019277-index-headers.html Edgar Link pending
0001564590-22-019277-index.html Edgar Link pending
0001564590-22-019277.txt Edgar Link pending
0001564590-22-019277-xbrl.zip Edgar Link pending
evok-10q_20220331.htm Edgar Link pending
evok-10q_20220331_htm.xml Edgar Link completed
evok-20220331.xsd Edgar Link pending
evok-20220331_cal.xml Edgar Link unprocessable
evok-20220331_def.xml Edgar Link unprocessable
evok-20220331_lab.xml Edgar Link unprocessable
evok-20220331_pre.xml Edgar Link unprocessable
evok-ex101_427.htm Edgar Link pending
evok-ex311_7.htm Edgar Link pending
evok-ex312_6.htm Edgar Link pending
evok-ex321_8.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gz0mxiaiyk4p000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending